The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
Centre for a Digital Society , Video here . These are my very rough talking points on pay or okay in full length (more than I actually had...
-
Y Combinator, video here. How is the Ferguson FTC going to tackle Big Tech? Simonetta Vezzoso @wavesblog.bsky.social · 4h Little Tec... -
US Senate, Here .
-
WSJ, here . "Trump hasn’t yet decided whether the administration will settle with the company over accusations that it bought Instagra... -
M.A.Franks, here .
-
G. Massarotto, here .
-
Y. Takamika, K. Shiozaki, here and here .
-
F. Castillo de la Torre, here .